AAptaTargets — Seed (estimated) · €2.7M
First funding round, €2.7M from Caixa Capital Risc and Inveready, to finish preclinical work on ApTOLL, its TLR4-blocking aptamer for acute ischemic stroke, and move it into Phase I/II trials. Later company material describes a first round of €5M including CDTI money, but press coverage at the time reported €2.7M of equity.
Lead unknown
RoundSeed (estimated)
Announced17 May 2017
CityMadrid
SectorHealthtech & Bio · Biotech
Source
L
L
